Recently, Pfizer's Elelyso, which is indicated to treat adults with Gaucher type 1 disease, was given a kosher certification from the Orthodox Union.
In this interview exclusive interview with Rare Disease Report, Rory O'Connor, Senior VP, Global Medical Affairs, Innovative Pharma Business, Pfizer Inc explains how the Orthodox Union examined the manufacturing facility to ensure that the medication met all applicable qualifications to be certified kosher.
Gaucher disease is a rare disease in the general population but is highly prevalent in the Ashkenazi Jewish community, so having a kosher certification is important to both Pfizer and the Gaucher patient population.
Gaucher disease is an inherited lysosomal storage disorder in which individuals have a deficiency in the enzyme glucocerebrosidase leading to the accumulation of the lipid glucosylceramide throughout the body. If not treated properly, symptoms of Gaucher disease can worsen and lead to permanent organ damage.
For more information about gaucher disease and Elelyso, visit www.elelyso.com